The Senate Armed Services Committee has embedded a series of directives into its FY2027 National Defense Authorization Act that collectively signal significant concern about the state of U.S. biological preparedness, from the readiness of individual servicemembers to the resilience of the defense pharmaceutical supply chain. The committee’s report, filed June 15, 2026, to accompany S. 4784, reflects growing unease on Capitol Hill about gaps in biodefense capabilities at a moment when federal public health funding is under sustained pressure.
The provisions relevant to health security and CBRNE defense planning span several areas: the military implications of mRNA vaccine funding cuts, anthrax countermeasure stockpiles, pharmaceutical supply chain security, AI-enabled biological threat detection, and the capacity for rapid concurrent detection of biological and chemical agents in the field.
mRNA Cuts Draw Scrutiny from Senate Defense Panel
In one of the most direct congressional responses yet to HHS’s August 2025 decision to cut approximately $500 million in federal funding for mRNA vaccine research, the Senate Armed Services Committee has directed the Secretary of Defense to brief lawmakers by March 1, 2027, on the national security implications of that decision. The committee noted that over 95 percent of active-duty servicemembers were vaccinated against COVID-19 by late 2021, with the majority receiving an mRNA vaccine, and expressed concern that cuts to vaccine research and regulatory uncertainty for new vaccines could affect servicemember health and military readiness.
The required briefing must address existing DoD vaccine research priorities and projects, funding levels over the past five years, regulatory pathway challenges for new vaccines, and the specific risks to servicemembers and readiness if those priorities are not met. The directive stops short of reversing or condemning the HHS decision, but its inclusion in the NDAA report reflects the committee’s view that the downstream military consequences of civilian public health funding decisions warrant formal accounting.
Anthrax Countermeasures and Pharmaceutical Supply Chains
The report singles out anthrax as the leading biological agent threat posed by malign actors to U.S. servicemembers both abroad and at home, and expresses concern that the Department of Defense and its interagency partners are not fully meeting requirements for anthrax countermeasures, including both antitoxins and prophylactics. The committee directs the Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and Biological Defense Policy and Programs to brief lawmakers by March 31, 2027, on strategic plans for stockpiling, sustainability, and forward-deployment of anthrax countermeasures, including replenishment of current stocks.
On pharmaceutical supply chains more broadly, the committee cited a prior DoD Inspector General report finding that the department had not adequately mitigated risks from its reliance on foreign suppliers, lacked implementing guidance on supply chain risk management, and that this reliance constituted a public health, readiness, and national security risk. The committee directed a briefing by March 1, 2027, covering short-term risk mitigation for pharmaceuticals sourced from foreign entities of concern, efforts to encourage domestic and allied manufacturing investment, and plans to leverage existing medical countermeasure stockpiles to alleviate potential disruptions.
Biological Threat Intelligence and Detection Capabilities
The committee directed the Under Secretary of Defense for Intelligence and Security to ensure that biological weapons threats receive appropriate prioritization within defense intelligence organizations. Specific actions required include directing that the next Defense Intelligence Strategy explicitly address the biological threat, providing formal input to the National Intelligence Priorities Framework on biological intelligence needs, and adjusting Military Intelligence Program planning and budgeting to reflect biological threat priorities. A briefing on implementation is required by March 31, 2027.
Separately, the committee directed a briefing on AI-enabled biological threat detection, citing DARPA-supported advances in AI-based biological sequence analysis and noting that barriers remain to transitioning such capabilities from research into operational biosurveillance and early warning systems.
On detection capabilities in the field, the committee noted that aerosol biological and chemical agents are both easy and inexpensive to produce and represent growing threats to military operational readiness. It cited ongoing Russian chemical weapons activities, including violations of the Biological and Chemical Weapons Conventions as observed in Ukraine, and Chinese biological and chemical activities, as drivers of renewed urgency. The Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and Biological Defense Policy and Programs was directed to brief lawmakers by March 31, 2027, on requirements for sensors capable of detecting biological and chemical agents rapidly and concurrently in operational environments.
AI Tools for Medical Countermeasures Development
In a provision with direct relevance to the broader countermeasure development ecosystem, the committee directed the Secretary of Defense to develop and deliver a strategy for leveraging AI tools in medical countermeasure development by December 1, 2027. The strategy must assess the current and projected biological and chemical threat landscape, identify near- and long-term countermeasure platform priorities, propose mechanisms for interagency coordination, and identify any policy or legislative changes needed for implementation.
A Defense-Side Response to Civilian Funding Cuts
Taken together, the committee’s directives in the FY2027 NDAA paint a picture of a legislative body attempting to use the defense authorization process to backstop gaps that have emerged, or risk becoming entrenched, on the civilian public health side. The White House FY2027 budget proposal, released April 4, 2026, proposed cutting BARDA by nearly $395.5 million and reducing the Strategic National Stockpile by $61.8 million, moves that public health advocates have warned could hollow out the domestic medical countermeasure pipeline. The NDAA provisions do not restore those cuts directly, but they impose accountability requirements and direct DoD to identify and address risks that flow from them.
Sources and further reading:
Senate Report 119-127, National Defense Authorization Act for Fiscal Year 2027 – U.S. Government Publishing Office
White House FY2027 Budget Would Cut CDC Funding by 40%, Eliminate Dozens of Public Health Programs – Global Biodefense
Abandoning mRNA: Why HHS’ Vaccine Retreat Puts Public Health Security at Risk – Global Biodefense